Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hyaluronan-binding proteins, or hyaladherins, are a class of molecules that bind selectively to hyaluronic acid, a major glycosaminoglycan of the extracellular matrix. They perform key structural and signaling functions, mediating cell adhesion, migration, and communication. Prominent examples include CD44, RHAMM, LYVE-1, Stabilin-2 (HARE), versican, and aggrecan. These proteins regulate diverse biological processes, including tissue hydration, inflammation, tumor metastasis, and tissue repair. Aberrant HA binding and turnover are implicated in diseases such as cancer, fibrosis, arthritis, and neurodegenerative disorders.
Mechanisms include enzymatic degradation of hyaluronic acid (e.g., hyaluronidase), blocking HA-receptor interactions (e.g., anti-CD44 antibodies), modulation of ECM structure via inhibition or enhancement of HA-protein binding, and disrupting HA accumulation to enhance drug penetration in tumors.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hyaluronan-binding protein (HABP).